Psychedelic and ketamine research trials in Germany
Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
15 registered studies are counted in Germany. By compound: 4 psilocybin, 1 MDMA, 1 LSD and 9 ketamine. By registry status: 4 recruiting, 2 active, not recruiting and 9 completed. By phase: 4 phase 2, 6 phase 3, 2 phase 4 and 3 not applicable. Reported start years run from 2014 (earliest) to 2025 (latest). Studies are linked to 65 institutions.
Country is taken from the research sites linked to each registry record. A study counts once per country and may appear in several countries. Compound counts may overlap. This directory covers its linked compound hubs; the research map and MCP connector also include other compounds. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
4 of the 15 counted studies are listed in the registry as recruiting (4) or not yet recruiting (0), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Registry dates | Institution and city |
|---|---|---|---|---|---|
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | NCT06793397 | Recruiting | Phase 3 | Source start: 2025-12-10 (actual)Source date detailsStart: 2025-12-10 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-06-07 (precision: day; source type: ESTIMATED; estimated) Study completion: 2027-08-09 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-10-30 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Central Institute of Mental Health, Mannheim; University Hospital Frankfurt, Frankfurt am Main; Charité Universitaetsmedizin Berlin, Berlin; Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Homburg |
| At-Home tDCS as Maintenance Therapy | NCT07269964 | Recruiting | Not applicable | Source start: 2024-10-01 (actual)Source date detailsStart: 2024-10-01 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-08-29 (precision: day; source type: ESTIMATED; estimated) Study completion: 2026-11-29 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.483Z; registry revision: 2025-12-08 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Munich,, München; Department of Psychiatry and Psychotherapy, Technical University of Munich, University Hospital, München |
| The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. | NCT05973851 | Recruiting | Phase 3 | Source start: 2024-08-31 (actual)Source date detailsStart: 2024-08-31 (precision: day; source type: ACTUAL; actual) Primary completion: 2028-06-30 (precision: day; source type: ESTIMATED; estimated) Study completion: 2028-06-30 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.980Z; registry revision: 2025-09-26 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | LWL-Klinik Dortmund, Bereich Forschung & Wissenschaft, Dortmund; Westfälische Wilhelms-Universität Münster, Münster; University Hospital Frankfurt am Main - Goethe University, Frankfurt am Main; Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, Bielefeld |
| Pharmacologic Treatment Augmentation in Chronic Depression | NCT06410599 | Recruiting | Phase 2 | Source start: 2024-04-29 (actual)Source date detailsStart: 2024-04-29 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-05 (precision: month; source type: ESTIMATED; estimated) Study completion: 2026-07 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.400Z; registry revision: 2025-03-27 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Universitätsklinikum Jena - Klinik für Psychiatrie und Psychotherapie, Jena; Universitätsklinikum Tübingen - Klinik für Psychiatrie und Psychotherapie, Tübingen |
At a glance
- 15 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 4 |
| MDMA | 1 |
| LSD | 1 |
| Ketamine | 9 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 4 | 27% |
| Active, not recruiting | 2 | 13% |
| Completed | 9 | 60% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 2 | 4 | 27% |
| Phase 3 | 6 | 40% |
| Phase 4 | 2 | 13% |
| Not applicable | 3 | 20% |
Registry-listed start years
| Start year | Studies |
|---|---|
| 2024 and later | 5 |
| 2020 to 2023 | 6 |
| 2015 to 2019 | 3 |
| 2010 to 2014 | 1 |
All counted studies
All 15 counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Registry dates | Institution and city |
|---|---|---|---|---|---|
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | NCT06793397 | Recruiting | Phase 3 | Source start: 2025-12-10 (actual)Source date detailsStart: 2025-12-10 (precision: day; source type: ACTUAL; actual) Primary completion: 2027-06-07 (precision: day; source type: ESTIMATED; estimated) Study completion: 2027-08-09 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-10-30 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Central Institute of Mental Health, Mannheim; University Hospital Frankfurt, Frankfurt am Main; Charité Universitaetsmedizin Berlin, Berlin; Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Homburg |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | NCT06809595 | Active, not recruiting | Phase 3 | Source start: 2025-01-29 (actual)Source date detailsStart: 2025-01-29 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-08-13 (precision: day; source type: ACTUAL; actual) Study completion: 2027-05 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-09-04 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Central Institute of Mental Health, Mannheim; Klinik für Psychiatrie und Psychotherapie, Abt: Allgemeine Psychiatrie und Psychotherapie, Tübingen; OVID Clinic Berlin, Berlin; Department of Psychiatry and Psychotherapy Campus Charité Mitte Charité Universitätsmedizin Berlin, Berlin |
| At-Home tDCS as Maintenance Therapy | NCT07269964 | Recruiting | Not applicable | Source start: 2024-10-01 (actual)Source date detailsStart: 2024-10-01 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-08-29 (precision: day; source type: ESTIMATED; estimated) Study completion: 2026-11-29 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.483Z; registry revision: 2025-12-08 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Munich,, München; Department of Psychiatry and Psychotherapy, Technical University of Munich, University Hospital, München |
| The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. | NCT05973851 | Recruiting | Phase 3 | Source start: 2024-08-31 (actual)Source date detailsStart: 2024-08-31 (precision: day; source type: ACTUAL; actual) Primary completion: 2028-06-30 (precision: day; source type: ESTIMATED; estimated) Study completion: 2028-06-30 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.980Z; registry revision: 2025-09-26 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | LWL-Klinik Dortmund, Bereich Forschung & Wissenschaft, Dortmund; Westfälische Wilhelms-Universität Münster, Münster; University Hospital Frankfurt am Main - Goethe University, Frankfurt am Main; Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, Bielefeld |
| Pharmacologic Treatment Augmentation in Chronic Depression | NCT06410599 | Recruiting | Phase 2 | Source start: 2024-04-29 (actual)Source date detailsStart: 2024-04-29 (precision: day; source type: ACTUAL; actual) Primary completion: 2026-05 (precision: month; source type: ESTIMATED; estimated) Study completion: 2026-07 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:17.400Z; registry revision: 2025-03-27 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Universitätsklinikum Jena - Klinik für Psychiatrie und Psychotherapie, Jena; Universitätsklinikum Tübingen - Klinik für Psychiatrie und Psychotherapie, Tübingen |
| Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | NCT05711940 | Active, not recruiting | Phase 3 | Source start: 2023-02-14 (actual)Source date detailsStart: 2023-02-14 (precision: day; source type: ACTUAL; actual) Primary completion: 2025-11-13 (precision: day; source type: ACTUAL; actual) Study completion: 2026-12 (precision: month; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:16.639Z; registry revision: 2026-08-10 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Johann Wolfgang Goethe-Universitaet Frankfurt am Main - Klinik fuer Psychiatrie, Psychosomatik und Psychotherapie, Frankfurt; Charite-Universitaetsmedizin Berlin, Berlin; ZiP Campus Luebeck, Lübeck |
| Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression | NCT04670081 | Completed | Phase 2 | Source start: 2021-06-10 (actual)Source date detailsStart: 2021-06-10 (precision: day; source type: ACTUAL; actual) Primary completion: 2024-02-27 (precision: day; source type: ACTUAL; actual) Study completion: 2024-12-11 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.488Z; registry revision: 2025-01-20 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy, Berlin; Central Institute of Mental Health (CIMH), Mannheim |
| A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment | NCT04829318 | Completed | Phase 4 | Source start: 2021-04-26 (actual)Source date detailsStart: 2021-04-26 (precision: day; source type: ACTUAL; actual) Primary completion: 2024-07-22 (precision: day; source type: ACTUAL; actual) Study completion: 2024-07-22 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.827Z; registry revision: 2025-09-18 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Somni Bene GmbH, Schwerin; Klinische Forschung Schwerin GmbH, Schwerin; Medizinisches Versorgungszentrum LiO GmbH, Berlin; Praxis Dr. med. Kirsten Hahn, Berlin; Klinische Forschung Hamburg, Hamburg; Klinikum Dortmund gGmbH, Dortmund; Pharmakologisches Studienzentrum Chemnitz GmbH, Mittweida; Danuvius Klinik Pfaffenhofen Fachklinik für Psychiatrie, Psychotherapie und Psychosomatik, Pfaffenhofen; Oberhavel Kliniken GmbH, Hennigsdorf; Universitätsklinikum Freiburg - Abteilung für Psychiatrie u. Psychotherapie mit Poliklinik, Freiburg im Breisgau |
| A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder | NCT04338321 | Completed | Phase 3 | Source start: 2020-08-21 (actual)Source date detailsStart: 2020-08-21 (precision: day; source type: ACTUAL; actual) Primary completion: 2022-01-20 (precision: day; source type: ACTUAL; actual) Study completion: 2022-07-15 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:12.343Z; registry revision: 2025-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Universitatsklinikum Bonn, Bonn; Panakeia - Arzneimittelforschung GmbH, Leipzig; Klinikum der Hansestadt Stralsund GmbH-Ambulanz-Klinik für Psychiatrie und Psychotherapie - Germany, Stralsund; Evangelisches Krankenhaus Bethanien gGmbH, Greifswald; Charite Campus Benjamin Franklin, Berlin; Klinikum Chemnitz gGmbH, Chemnitz; Somni Bene GmbH, Schwerin; Klinische Forschung Schwerin GmbH, Schwerin; Medizinisches Versorgungszentrum LiO GmbH, Berlin; Medizinische Hochschule Hannover, Hanover; Alexander Schulze - Germany, Berlin; Rheinhessen Fachklinik Alzey, Alzey; Ruppiner Kliniken, Neuruppin; Universitatsklinikum Jena, Jena; Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz; Georg August Universitat Universitatsmedizin Gottingen, Göttingen; Universitaetsklinikum der RWTH Aachen, Aachen; Praxis Dr. med. Kirsten Hahn, Berlin; Klinische Forschung Hamburg, Hamburg; Universitatsklinikum Munster, Münster; Universitatsklinikum Carl Gustav Carcus Dresden, Dresden; Klinikum Dortmund gGmbH, Dortmund; Pharmakologisches Studienzentrum Chemnitz GmbH, Mittweida; Universitätsklinikum des Saarlandes, Homburg; Universitaetsklinikum Magdeburg A.oe.R, Magdeburg; Universitaetsklinik Hamburg-Eppendorf, Hamburg; Vivantes Klinikum Spandau, Berlin; Klinische Forschung Hannover-Mitte GmbH, Hanover; Universitatsklinikum Frankfurt, Frankfurt am Main; Danuvius Klinik Pfaffenhofen Fachklinik für Psychiatrie, Psychotherapie und Psychosomatik, Pfaffenhofen; Oberhavel Kliniken GmbH, Hennigsdorf; Carl-Thiem-Klinikum Cottbus gGmbH, Cottbus; Johanniter Krankenhaus Oberhausen, Oberhausen; Emovis GmbH, Berlin; Universität Heidelberg, Heidelberg; SRH Waldklinikum Gera GmbH, Gera; Praxis Prof. Steinwachs, Nuremberg; Universitätsklinikum Freiburg - Abteilung für Psychiatrie u. Psychotherapie mit Poliklinik, Freiburg im Breisgau |
| Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study | NCT04030169 | Completed | Phase 2 | Source start: 2020-06-24 (actual)Source date detailsStart: 2020-06-24 (precision: day; source type: ACTUAL; actual) Primary completion: 2023-12-14 (precision: day; source type: ACTUAL; actual) Study completion: 2023-12-15 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.077Z; registry revision: 2025-01-28 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Charité - Universitätsmedizin, Berlin Campus Benjamin Franklin, Berlin |
| Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine | NCT04156035 | Completed | Not applicable | Source start: 2020-03-10 (actual)Source date detailsStart: 2020-03-10 (precision: day; source type: ACTUAL; actual) Primary completion: 2020-12-10 (precision: day; source type: ACTUAL; actual) Study completion: 2020-12-10 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.077Z; registry revision: 2021-03-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Medical School Berlin, Berlin |
| Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers | NCT05320991 | Completed | Phase 4 | Source start: 2019-06-15 (actual)Source date detailsStart: 2019-06-15 (precision: day; source type: ACTUAL; actual) Primary completion: 2020-09-27 (precision: day; source type: ACTUAL; actual) Study completion: 2020-09-27 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:16.228Z; registry revision: 2022-04-18 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn |
| The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | NCT03775200 | Completed | Phase 2 | Source start: 2019-03-01 (actual)Source date detailsStart: 2019-03-01 (precision: day; source type: ACTUAL; actual) Primary completion: 2021-07-30 (precision: day; source type: ACTUAL; actual) Study completion: 2021-09-27 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:14.687Z; registry revision: 2023-04-24 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin, Berlin |
| 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide | NCT03039192 | Completed | Phase 3 | Source start: 2017-06-09 (actual)Source date detailsStart: 2017-06-09 (precision: day; source type: ACTUAL; actual) Primary completion: 2018-12-18 (precision: day; source type: ACTUAL; actual) Study completion: 2018-12-18 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:14.289Z; registry revision: 2025-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Klinik für Psychiatrie und Psychotherapie, Freiburg im Breisgau; Vivantes Humboldt Klinikum, Berlin; Universitatsklinikum Frankfurt, Frankfurt am Main |
| Effects of Ketamine on Eye Movements, Perception and Brain Function | NCT02701933 | Completed | Not applicable | Source start: 2014-04 (type unknown) Saved start 2014-04-01 differs from reported 2014-04; the saved day is not established by this observation. Source date detailsStart: 2014-04 (precision: month; source type: not reported; unknown) Primary completion: 2014-12 (precision: month; source type: ACTUAL; actual) Study completion: 2014-12 (precision: month; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:13.907Z; registry revision: 2016-03-08 (precision: day; source type: ESTIMATED; estimated). Source observations do not verify a different saved scalar or establish that an event occurred. | University of Bonn, Bonn |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | Ketamine
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 10 |
| Treatment-resistant depression | 6 |
| Anxiety | 1 |
| Post-traumatic stress disorder | 1 |
| Suicidal ideation and suicide risk | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | Israel | Brazil | France | China | Netherlands | Spain | Austria | Australia | Poland | Czech Republic | Ireland | Denmark | Sweden | Taiwan | Argentina | Belgium | Finland | Turkey | Greece | Hungary | Italy | Mexico | Bulgaria | Egypt | Norway | Pakistan | Portugal